Joann St Pierre, APRN
Women's Health · Houston, TXNPI 1922173053
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Axsome Therapeutics, Inc. at 41.5% of the total. 2025 is the largest year on record at $8,401, 2.8 times the $2,990 reported in 2021. Among women's health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 308 payments — averaging $49.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$6K
- AbbVie$4K
- Pfizer$1K
- UCB, Inc.$358
- Novartis$353
- Lilly USA, LLC$341
- plus $3K from 30 others
What the payments were for
- Consulting fees$6754%
- Speaking & faculty fees$7,51350%
- Travel & lodging$5794%
- Food & beverage$6,40842%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 24 | $6,301 |
| AbbVie(2 entities) | 102 | $4,206 |
| Pfizer | 15 | $1,103 |
| UCB, Inc. | 12 | $358 |
| Novartis | 22 | $353 |
| Lilly USA, LLC | 15 | $341 |
| Eisai Inc. | 12 | $305 |
| CSL Behring | 10 | $222 |
| Inspire Medical Systems, Inc. | 14 | $207 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $194 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $152 |
| Grifols USA, LLC | 6 | $145 |
| Sanofi | 5 | $136 |
| AstraZeneca | 6 | $135 |
| Amgen | 6 | $133 |
| Jazz Pharmaceuticals Inc. | 4 | $110 |
| Teva Pharmaceuticals USA, Inc. | 5 | $102 |
| Argenx US, Inc. | 4 | $84 |
| Neurocrine Biosciences, Inc. | 3 | $82 |
| Kyowa Kirin, Inc. | 3 | $66 |
| Acadia Pharmaceuticals Inc | 4 | $64 |
| SK Life Science, Inc. | 2 | $53 |
| Adamas Pharmaceuticals, Inc. | 2 | $49 |
| Biohaven Pharmaceuticals, Inc. | 3 | $49 |
| Ultragenyx Pharmaceutical Inc. | 1 | $27 |
| Merz Pharmaceuticals, LLC | 1 | $26 |
| Biogen | 2 | $26 |
| Abbott | 1 | $24 |
| Averitas Pharma Inc. | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $17 |
| Avion Pharmaceuticals | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Mallinckrodt Hospital Products Inc. | 1 | $12 |
| Insightec,inc | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Symbravo$5,746
- NURTEC ODT$675
- QULIPTA$125
- KISUNLA$122
- ZAVZPRET$115
How this compares
$15,175 in reported general payments places this provider in the 95th percentile of 609 women's health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 14 | $77,128 |
| UbrelvyUbrogepant | 13 | $20,466 |
| Nurtec OdtRimegepant Sulfate | 11 | $19,860 |
| Galantamine Hbr | 86 | $7,430 |
| Memantine Hcl | 177 | $7,087 |
| FingolimodFingolimod Hcl | 11 | $5,384 |
| Quetiapine Fumarate | 116 | $2,647 |
| Sertraline Hcl | 230 | $2,412 |
| Donepezil Hcl | 167 | $2,031 |
| Mirtazapine | 52 | $1,644 |
| Oxcarbazepine | 28 | $1,600 |
| Levetiracetam | 35 | $1,598 |
| Galantamine ErGalantamine Hbr | 11 | $1,433 |
| Gabapentin | 77 | $1,379 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 39 | $1,046 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $64 | $77,12814 claims |
| AbbVieUbrelvy | $4,206 | $20,46613 claims |
| PfizerNurtec Odt | $1,103 | $19,86011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 609 women's health providers in Texas.
Other women's health in Houston
- Lori WinkHouston$9K
- Andrea DunnHouston$6K
- Kim GustafsonHouston$4K
- Erica SmithHouston$4K
- Christie LouisHouston$3K
- Mary UmbleHouston$3K
- Kim OkewunmiHouston$3K
- Kathryn AckermanHouston$2K
- Evelyn TingGrapevine$89K
- Christina TrumanWaco$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.